Pacific Edge Limited announced that it had substantially completed a commercial agreement with Te Whatu Ora - Southern for the use of its non-invasive Cxbladder genomic biomarker tests. At this stage the contract remains unsigned. The business case is currently with Te Whatu Ora -Southern Management Team and following that it will enter an approvals cycle.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.094 NZD | 0.00% |
|
-2.08% | -19.66% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.66% | 46.67M | |
+32.78% | 52.85B | |
-7.23% | 38.87B | |
+35.03% | 38.24B | |
-11.12% | 26.79B | |
+11.84% | 26.16B | |
-18.50% | 19.9B | |
+37.52% | 13.18B | |
+29.25% | 12.24B | |
-3.01% | 11.79B |
- Stock Market
- Equities
- PEB Stock
- News Pacific Edge Limited
- Pacific Edge Limited Completes a Commercial Agreement with Te Whatu Ora Southern